Crizanlizumab does not affect mortality or the number of days free of respiratory or cardiovascular (CV) organ-support measures in hospitalized patients with COVID-19. A humanized monoclonal antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results